The FDA’s Move Towards More Transparent, Collaborative Approval Process Requires Robust Compliance Management Systems

In a recent article posted on Pharmaceutical Compliance Monitor, Dr. Frank Gozzo, president and CEO of Noverant, discusses the FDA's move towards a more transparent and collaborative approval process. He explains why this change is being made and how it requires companies within the pharmaceutical industry to maintain robust compliance management systems. To learn more about why strong compliance engines are important and the impact that they can have on developing a cooperative relationship between manufacturers and regulators, check out the full article.